繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-110

6场半全场18093:MB-110

6场半全场有多少奖金 www.dkpgas.com.cn

Indication
Hepatitis C
Product Advantages
superior inhibition capacity against prevalent HCV genotypes in Asia (1b, 2a and 3a)
Status
Obtained the investigational new drug (IND) approval from FDA for human clinical trial
Mechanism
Small molecule, highly active and selective inhibitor of NS5A protein of hepatitis C virus (HCV)
Potential Market
According to the statistics of the World Health Organization, about 700,000 people die of liver diseases related to hepatitis C every year. By 2015, the global market has reached 24 billion U.S. dollars. According to the IMS data, the global anti-hepatitis C drug will reach 36 billion U.S. dollars by 2020

Pre-clinical results

MB-110(NSFAI003, DBPR110) has better bioavailability and longer half-life
Good biological stability
 

Mechanism